MAPT and Alzheimer disease: In this study, we quantified a panel of plasma biomarkers of disease‐specific biomarkers of AD (Aβ42/40, and p‐tau‐181) together with AD‐nonspecific biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP).